Evidence map›Paper›PMID 38362406›Full record

ArticleChemical science2024

Aldehyde-mediated inhibition of asparagine biosynthesis has implications for diabetes and alcoholism.

Tobias John, Nadia Saffoon, John Walsby-Tickle, Svenja S Hester, Felix A Dingler, Christopher L Millington, James S O McCullagh, Ketan J Patel, Richard J Hopkinson, Christopher J Schofield

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Tobias JohnChemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford 12 Mansfield Road Oxford OX1 3TA UK christopher.schofield@chem.ox.ac.uk.ORCID https://orcid.org/0000-0002-6123-595X
Nadia SaffoonChemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford 12 Mansfield Road Oxford OX1 3TA UK christopher.schofield@chem.ox.ac.uk.
John Walsby-TickleChemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford 12 Mansfield Road Oxford OX1 3TA UK christopher.schofield@chem.ox.ac.uk.ORCID https://orcid.org/0000-0002-1287-9580
Svenja S HesterNuffield Department of Medicine, Target Discovery Institute, University of Oxford Oxford UK.
Felix A DinglerMRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital/Headley Way Oxford OX3 9DS UK.ORCID https://orcid.org/0000-0002-6297-2986
Christopher L MillingtonMRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital/Headley Way Oxford OX3 9DS UK.
James S O McCullaghChemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford 12 Mansfield Road Oxford OX1 3TA UK christopher.schofield@chem.ox.ac.uk.
Ketan J PatelMRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital/Headley Way Oxford OX3 9DS UK.
Richard J HopkinsonLeicester Institute for Structural and Chemical Biology and School of Chemistry, University of Leicester, Henry Wellcome Building Lancaster Road Leicester LE1 7RH UK richard.hopkinson@leicester.ac.uk.ORCID https://orcid.org/0000-0001-7610-8163
Christopher J SchofieldChemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford 12 Mansfield Road Oxford OX1 3TA UK christopher.schofield@chem.ox.ac.uk.ORCID https://orcid.org/0000-0002-0290-6565
University of Oxford · GBJohn Radcliffe Hospital · GBUniversity of Leicester · GB

Funding

Cancer Research UK 28285Medical Research Council MC_U105178811Medical Research Council MC_UU_00016/17Medical Research Council MC_UU_00029/1
6 · The paper itself

Abstract

Patients with alcoholism and type 2 diabetes manifest altered metabolism, including elevated aldehyde levels and unusually low asparagine levels. We show that asparagine synthetase B (ASNS), the only human asparagine-forming enzyme, is inhibited by disease-relevant reactive aldehydes, including formaldehyde and acetaldehyde. Cellular studies show non-cytotoxic amounts of reactive aldehydes induce a decrease in asparagine levels. Biochemical analyses reveal inhibition results from reaction of the aldehydes with the catalytically important N-terminal cysteine of ASNS. The combined cellular and biochemical results suggest a possible mechanism underlying the low asparagine levels in alcoholism and diabetes. The results will stimulate research on the biological consequences of the reactions of aldehydes with nucleophilic residues.

Identifiers

PMID38362406
PMCPMC10866355
OpenAlexW4390886760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.